The Parkwalk-managed University of Bristol Enterprise Fund has joined parent IP Group to become an investor in macular degeneration-focused spinout Exonate.

Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.

Nationwide Children’s Hospital spinout Celenex could fetch as much as $452m upon completion of milestones after progressing rare disease therapies conceived at the hospital’s collaborative program with Ohio State University.

Autonomous vehicle software spinout Oxbotica has secured IP Group, Parkwalk Advisors and Axa XL as investors in its first publicly-disclosed funding round.

TUM-founded Twaice Technologies has won backing from UVC Partners to deliver battery management software targeting electric vehicles.

Organic snack producer SMPL has been backed by Zell Founders Fund, a VC vehicle run by University of Michigan students.

University of Central Lancashire spinout Alusid has raised capital from Frontier IP to help fund a new factory for its building material made from recycled glass and porcelain.

The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.

Oxford VR is developing VR mental health applications with the help of funding from investors including the university and its OSI venture fund.

US-based website creation tool developer Strikingly has received more than $10m in a series A-plus round that featured CAS Holding.